JP2017514871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514871A5 JP2017514871A5 JP2016566909A JP2016566909A JP2017514871A5 JP 2017514871 A5 JP2017514871 A5 JP 2017514871A5 JP 2016566909 A JP2016566909 A JP 2016566909A JP 2016566909 A JP2016566909 A JP 2016566909A JP 2017514871 A5 JP2017514871 A5 JP 2017514871A5
- Authority
- JP
- Japan
- Prior art keywords
- glyx
- administering
- patient
- effective amount
- cognitive impairment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989183P | 2014-05-06 | 2014-05-06 | |
| US61/989,183 | 2014-05-06 | ||
| PCT/US2015/029477 WO2015171770A1 (en) | 2014-05-06 | 2015-05-06 | Combinations of nmdar modulating compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020083060A Division JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017514871A JP2017514871A (ja) | 2017-06-08 |
| JP2017514871A5 true JP2017514871A5 (enExample) | 2018-06-14 |
Family
ID=54392956
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566909A Pending JP2017514871A (ja) | 2014-05-06 | 2015-05-06 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2020083060A Pending JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2022116942A Pending JP2022159322A (ja) | 2014-05-06 | 2022-07-22 | Ｎｍｄａｒ調節化合物の組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020083060A Pending JP2020138973A (ja) | 2014-05-06 | 2020-05-11 | Ｎｍｄａｒ調節化合物の組合せ |
| JP2022116942A Pending JP2022159322A (ja) | 2014-05-06 | 2022-07-22 | Ｎｍｄａｒ調節化合物の組合せ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170072005A1 (enExample) |
| EP (1) | EP3139943A4 (enExample) |
| JP (3) | JP2017514871A (enExample) |
| KR (2) | KR20170013890A (enExample) |
| CN (1) | CN106659762A (enExample) |
| AU (1) | AU2015256075B2 (enExample) |
| BR (1) | BR112016025910A8 (enExample) |
| CA (1) | CA2947976A1 (enExample) |
| MX (1) | MX2016014581A (enExample) |
| RU (1) | RU2721948C2 (enExample) |
| WO (1) | WO2015171770A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2957898C (en) | 2014-09-15 | 2023-02-21 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists |
| WO2016049048A1 (en) * | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| US10221182B2 (en) | 2015-02-04 | 2019-03-05 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists |
| JP2018521007A (ja) * | 2015-05-22 | 2018-08-02 | ヴィスタゲン セラピューティクス、インコーポレイテッド | Ｌ−４−クロロキヌレニンの治療的使用 |
| US10584127B2 (en) | 2015-06-01 | 2020-03-10 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists |
| MX2018004632A (es) * | 2015-10-16 | 2018-11-09 | Scythian Biosciences Inc | Metodos y composiciones para el tratamiento de una lesion cerebral traumatica. |
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| CN109475500A (zh) * | 2016-05-25 | 2019-03-15 | 财团法人卫生研究院 | 用于减低氯胺酮致精神病状副作用及成瘾疾患的方法与组合物 |
| WO2018098128A1 (en) | 2016-11-22 | 2018-05-31 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| CN107550907A (zh) * | 2017-08-29 | 2018-01-09 | 昆明医科大学 | 治疗精神分裂症的药物及验证药物的动物模型构建方法 |
| JP2021505668A (ja) * | 2017-12-05 | 2021-02-18 | ノーレックス インコーポレイテッド | 併用療法（睡眠障害およびｃｎｓ障害）において使用するためのｎｍｄａ受容体モジュレーター（ラパスチネル）の組合せ |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| CN110343050B (zh) | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| US20220024976A1 (en) * | 2019-01-11 | 2022-01-27 | Naurex Inc. | Salt and crystalline forms of rapastinel |
| US20220117951A1 (en) * | 2019-02-14 | 2022-04-21 | Algernon Pharmaceuticals Inc. | Compositions and methods for treating idiopathic pulmonary fibrosis |
| WO2021081624A1 (en) | 2019-10-28 | 2021-05-06 | Algernon Pharmaceuticals Inc. | Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives |
| CN113234036B (zh) * | 2021-05-12 | 2023-07-14 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
| KR20230056971A (ko) * | 2021-10-21 | 2023-04-28 | 삼육대학교산학협력단 | 신규 케타민 유도체를 포함하는 우울증 예방 또는 치료용 약학적 조성물 |
| EP4587019A2 (en) | 2022-09-14 | 2025-07-23 | The Board of Trustees of the Leland Stanford Junior University | Compositions of iboga alkaloids and methods of treatment |
| WO2025065271A1 (en) * | 2023-09-26 | 2025-04-03 | Liangzhu Laboratory | Methods and devices for treating depression |
| WO2025124571A1 (zh) * | 2023-12-14 | 2025-06-19 | 斯莱普泰(上海)生物医药科技有限公司 | Nmda受体拮抗剂及其用途 |
| CN119174765A (zh) * | 2024-09-04 | 2024-12-24 | 复旦大学附属中山医院 | Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| MXPA05012493A (es) * | 2003-05-27 | 2006-05-25 | Forest Laboratories | Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo. |
| GB0523998D0 (en) * | 2005-11-25 | 2006-01-04 | Merck Sharp & Dohme | Therapeutic agents |
| US20090275597A1 (en) * | 2008-05-02 | 2009-11-05 | Forest Laboratories Holdings Limited | Methods of treating cns disorders |
| CA2729292C (en) * | 2008-07-03 | 2013-09-03 | Amira Pharmaceuticals, Inc. | Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors |
| CN102271677A (zh) * | 2008-12-29 | 2011-12-07 | 凡德贝尔大学 | 3.1.0双环G1yT1抑制剂及其制备和使用方法 |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| RU2589692C2 (ru) * | 2010-06-15 | 2016-07-10 | Грюненталь Гмбх | Фармацевтическая комбинация для лечения от боли |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
-
2015
- 2015-05-06 WO PCT/US2015/029477 patent/WO2015171770A1/en not_active Ceased
- 2015-05-06 RU RU2016146714A patent/RU2721948C2/ru active
- 2015-05-06 CA CA2947976A patent/CA2947976A1/en not_active Abandoned
- 2015-05-06 MX MX2016014581A patent/MX2016014581A/es unknown
- 2015-05-06 KR KR1020167034031A patent/KR20170013890A/ko not_active Ceased
- 2015-05-06 JP JP2016566909A patent/JP2017514871A/ja active Pending
- 2015-05-06 EP EP15789211.8A patent/EP3139943A4/en not_active Withdrawn
- 2015-05-06 US US15/309,390 patent/US20170072005A1/en not_active Abandoned
- 2015-05-06 KR KR1020227022906A patent/KR20220102662A/ko not_active Ceased
- 2015-05-06 AU AU2015256075A patent/AU2015256075B2/en not_active Ceased
- 2015-05-06 BR BR112016025910A patent/BR112016025910A8/pt not_active Application Discontinuation
- 2015-05-06 CN CN201580031430.2A patent/CN106659762A/zh active Pending
-
2020
- 2020-05-11 JP JP2020083060A patent/JP2020138973A/ja active Pending
-
2022
- 2022-07-22 JP JP2022116942A patent/JP2022159322A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52257A (fr) | Compositions pharmaceutiques comprenant blautia et leur administration orale | |
| EP3558424A4 (en) | DRUG DELIVERY SYSTEMS AND METHODS | |
| IL254207B (en) | Oral care compositions and methods of use | |
| EP3399972A4 (en) | LOW-DOSED THERAPEUTIC TREATMENT | |
| JP2016518337A5 (enExample) | ||
| HUE053309T2 (hu) | Új sók és gyógyászati készítmények gyulladásos betegségek kezelésére | |
| EP3681479A4 (en) | METHOD OF ADMINISTRATION AND TREATMENT | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| JP2015503422A5 (enExample) | ||
| PL4335517T3 (pl) | Podawanie i dawkowanie diaminofenotiazyn | |
| HUE058731T2 (hu) | Gyógyászati készítmények, kezelési eljárások és ezek alkalmazásai | |
| IL260955A (en) | A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure | |
| HUE060496T2 (hu) | Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére | |
| PL3229794T3 (pl) | Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego | |
| HUE071358T2 (hu) | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk | |
| HUE058354T2 (hu) | Hidrofil bevonattal rendelkezõ higiénikus orvosi eszközök és eljárások azok kialakítására | |
| JP2015522522A5 (enExample) | ||
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| MX2017003513A (es) | Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia. | |
| HUE062784T2 (hu) | Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| HUE066272T2 (hu) | Terápiás szer az amiotrófiás laterálszklerózisra és a kezelésre szolgáló készítmény | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| UA118474C2 (uk) | (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині | |
| HUE056739T2 (hu) | Páciensek kezelése rivaroxaban és verapamil együttes beadásával |